Oxford Immunotec Global logo

OXFD - Oxford Immunotec Global Share Price

$21.99 0.0  0.0%

Last Trade - 05/03/21

Sector
Healthcare
Size
Mid Cap
Market Cap £406.4m
Enterprise Value £290.3m
Revenue £41.4m
Position in Universe 3322nd / 6651
Bullish
Bearish
Unlock OXFD Revenue
Momentum
Relative Strength (%)
1m +2.97%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -4.84%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
49.5 62.8 47.0 54.7 59.8 73.7 58.8 82.2 +8.3%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, OxfordImmunotec Global PLC revenues decreased 30% to $39.2M. Netloss before extraordinary items totaled $15M vs. income of$280K. Revenues reflect United States segment decrease of40% to $11.4M, Asia segment decrease of 24% to $22M. Netloss reflects Interest income decrease of 78% to $770K(income), Research and development - Balancing val increaseof 26% to $7.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

OXFD Revenue Unlock OXFD Revenue

Net Income

OXFD Net Income Unlock OXFD Revenue

Normalised EPS

OXFD Normalised EPS Unlock OXFD Revenue

PE Ratio Range

OXFD PE Ratio Range Unlock OXFD Revenue

Dividend Yield Range

OXFD Dividend Yield Range Unlock OXFD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
OXFD EPS Forecasts Unlock OXFD Revenue
Profile Summary

Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated August 16, 2013
Public Since November 22, 2013
No. of Shareholders: 8
No. of Employees: 273
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 25,577,834
Free Float (0.0%)
Eligible for
ISAs
SIPPs
OXFD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for OXFD
Upcoming Events for OXFD
Frequently Asked Questions for Oxford Immunotec Global
What is the Oxford Immunotec Global share price?

As of 05/03/21, shares in Oxford Immunotec Global are trading at $21.99, giving the company a market capitalisation of £406.4m. This share price information is delayed by 15 minutes.

How has the Oxford Immunotec Global share price performed this year?

Shares in Oxford Immunotec Global are currently trading at $21.99 and the price has moved by 64.84% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oxford Immunotec Global price has moved by 30.02% over the past year.

What are the analyst and broker recommendations for Oxford Immunotec Global?

Of the analysts with advisory recommendations for Oxford Immunotec Global, there are there are currently 1 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Oxford Immunotec Global is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Oxford Immunotec Global next release its financial results?

Oxford Immunotec Global is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Oxford Immunotec Global dividend yield?

Oxford Immunotec Global does not currently pay a dividend.

Does Oxford Immunotec Global pay a dividend?

Oxford Immunotec Global does not currently pay a dividend.

When does Oxford Immunotec Global next pay dividends?

Oxford Immunotec Global does not currently pay a dividend.

How do I buy Oxford Immunotec Global shares?

To buy shares in Oxford Immunotec Global you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Oxford Immunotec Global?

Shares in Oxford Immunotec Global are currently trading at $21.99, giving the company a market capitalisation of £406.4m.

Where are Oxford Immunotec Global shares listed? Where are Oxford Immunotec Global shares listed?

Here are the trading details for Oxford Immunotec Global:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: OXFD
What kind of share is Oxford Immunotec Global?

Based on an overall assessment of its quality, value and momentum, Oxford Immunotec Global is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Oxford Immunotec Global share price forecast 2021?

Shares in Oxford Immunotec Global are currently priced at $21.99. At that level they are trading at 2.32% discount to the analyst consensus target price of 0.00.

Analysts covering Oxford Immunotec Global currently have a consensus Earnings Per Share (EPS) forecast of -0.605 for the next financial year.

How can I tell whether the Oxford Immunotec Global share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oxford Immunotec Global. Over the past six months, the relative strength of its shares against the market has been 58.97%. At the current price of $21.99, shares in Oxford Immunotec Global are trading at 43.91% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Oxford Immunotec Global PE Ratio?

We were not able to find PE ratio data for Oxford Immunotec Global.

Who are the key directors of Oxford Immunotec Global?

Oxford Immunotec Global's management team is headed by:

Peter Wrighton-Smith - CEO
Patricia Randall - IND
Richard Sandberg - IND
Herman Rosenman - IND
Ronald Andrews - IND
Patrick Balthrop - CHM
Mark Klausner - IND
Matthew McLaughlin - CFO
Janet Kidd - GCN
Who are the major shareholders of Oxford Immunotec Global?

Here are the top five shareholders of Oxford Immunotec Global based on the size of their shareholding:

Polar Capital LLP Investment Advisor/Hedge Fund
Percentage owned: 10.04% (2.57m shares)
Magnetar Capital Partners LP Investment Advisor/Hedge Fund
Percentage owned: 7.75% (1.98m shares)
Polar Capital Funds Plc - Healthcare Opportunities Fund Mutual Fund
Percentage owned: 6.6% (1.69m shares)
Senvest Management, LLC Hedge Fund
Percentage owned: 5.75% (1.47m shares)
Alyeska Investment Group, L.P. Hedge Fund
Percentage owned: 5.24% (1.34m shares)
Similar to OXFD
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.